POPULARITY
Categories
Moderator: James P. Rathmell, M.D. Participants: Carmen Bozic, M.D. Articles Discussed: Suzetrigine, a Nonopioid NaV1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials Suzetrigine: First in a New Class of Nonopioid Analgesics for Acute Pain
In today's episode, supported by Revolution Medicines, we spoke with Kathryn C. Arbour, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, about 2 important abstracts presented at the 2024 AACR Annual Meeting that explore novel RAS-targeted approaches in non–small cell lung cancer (NSCLC). Our discussion focused on early clinical findings with zoldonrasib (RMC-9805) and daraxonrasib (RMC-6236), both of which are RAS(ON) inhibitors under investigation for the treatment of patients with RAS-mutant NSCLC. Zoldonrasib, a KRAS G12D-selective tri-complex inhibitor, was evaluated in a phase 1 trial (NCT06040541) in patients with previously treated, advanced KRAS G12D–mutated solid tumors, including NSCLC. Daraxonrasib, a multi-selective RAS(ON) inhibitor, was highlighted in another phase 1 trial (NCT05379985) in patients with advanced RAS-mutant tumors, including previously treated NSCLC; notably, this AACR presentation focused on the association between early on-treatment circulating tumor DNA level reduction and clinical response with the agent. In this episode, Dr Arbour shared insights into the mechanisms of action behind these therapies, their respective clinical trial designs, and the potential implications that early data with the agents may have for the evolving RAS-mutant NSCLC treatment paradigm.
Eric Roeland, MD, FAAHPM, FASC, Associate Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine, OHSUMolly Thomas, MD, PhD, Assistant Professor of Medicine, Division of Gastroenterology & Hepatology, Assistant Professor of Cell, Developmental & Cancer Biology, School of Medicine, OHSUCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link: https://forms.office.com/r/j8tvnSw5cd (or copy & paste into your browser)Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee Disclosure: The planning committee and have indicated no relevant financial relationships with an ACCME-defined ineligible company. Their planning contributions were evidence-based and unbiased. Faculty Disclosure: Eric Roeland, MD has indicated relevant financial relationships with ACCME-defined ineligible companies: Scientific Advisory Board (Napo Pharmaceuticals); Expert Witness (Heron Pharmaceuticals); Research (Pfizer). All others in control of content have indicated no relevant financial relationship with an ACCME-defined commercial interest. All clinical content presented is evidence-based and unbiased. All financial relationships have been mitigated.Original Date: May 6, 2025End Date: May 6, 2026
Eric Roeland, MD, FAAHPM, FASC, Associate Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine, OHSUMolly Thomas, MD, PhD, Assistant Professor of Medicine, Division of Gastroenterology & Hepatology, Assistant Professor of Cell, Developmental & Cancer Biology, School of Medicine, OHSUCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link: https://forms.office.com/r/j8tvnSw5cd (or copy & paste into your browser)Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee Disclosure: The planning committee and have indicated no relevant financial relationships with an ACCME-defined ineligible company. Their planning contributions were evidence-based and unbiased. Faculty Disclosure: Eric Roeland, MD has indicated relevant financial relationships with ACCME-defined ineligible companies: Scientific Advisory Board (Napo Pharmaceuticals); Expert Witness (Heron Pharmaceuticals); Research (Pfizer). All others in control of content have indicated no relevant financial relationship with an ACCME-defined commercial interest. All clinical content presented is evidence-based and unbiased. All financial relationships have been mitigated.Original Date: May 6, 2025End Date: May 6, 2026
Sodium Glucose Cotransporter-2 Inhibitors (SGLT2) have demonstrated improvement in patient outcomes across several disease states including patients with type 2 diabetes, heart failure and chronic kidney disease. Despite guideline recommendations for the use of these agents in each of these disease states, utilization of SGLT2 remains relatively low. This podcast discusses some of the barriers to utilization of SGLT2 and strategies to increase uptake of this therapy among patients with diabetes, heart failure and chronic kidney disease. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
AUA2025: PARP-Inhibitor Combination Treatments for the Urologic Care Team CME Available: https://auau.auanet.org/node/42822 At the conclusion of this CME activity, participants will be able to: 1. Apply the mechanism of action of PARP inhibitors and the rationale for using them in patients with advanced prostate cancer. 2. Recognize the role and importance of genetic testing in patients with mCRPC and the implications of germline mutations on response to therapy. 3. Identify best practices and utilize available guidelines for patients with mCRPC to optimize treatment success and oncologic outcomes. 4. Recognize when to use PARP inhibitors as monotherapy, the rationale and indications for combination therapy, and appropriate treatment sequencing. 5. Successfully counsel patients on the possible adverse events associated with PARP inhibitor therapies alone or in combination. ACKOWLEDGEMENTS Support provided by independent educational grants from: AstraZeneca Merck & Co., Inc.
Because of breast cancer, fear of cancer recurrence is a permanent part of my life. I continue taking tamoxifen to reduce my risk of the cancer coming back. In this episode I share my thoughts on the good quality of life I have while taking tamoxifen. I value my strong body and theimited side-effects I have now. I also value a life with the lowest possible risk of breast cancer recurrence. I look forward to discussing what it might mean to switch to an aromatase inhibitor, in terms of further lowering the risk of recurrence and potentially experiencing more serious side-effects, with my oncologist On more than one occasion, the oncologist has brought up endocrine therapy and the possibility of switching from tamoxifen to an aromatase inhibitor “in the future”. Even my breast surgeon provided a quick plug for the lower risk of recurrence associated with taking aromatase inhibitors, compared to tamoxifen, without highlighting any of the aromatase inhibitor side-effects. Determining what might be the best endocrine therapy for me to prevent recurrence is not going to be easy. So far, neither doctor has done a deep dive into the different side-effects among the two drugs or what a change might do to overall health and quality of life. Thank you for listening to my story! If you'd like to be the first to receive updates and exclusive content from the upcoming Breast Cancer Life newsletter, please email me at connect@breastcancerlife.org. I'd love to have you on the list! LET'S CONNECT: connect@breastcancerlife.org Follow us on Pinterest
Brian Flesner, DVM, MS, DACVIM (Oncology), discusses the recently opened clinical trial studying an Autologous Cancer Vaccine with Checkpoint Inhibitor for the Treatment of Canine Osteosarcoma.The purpose of this study is to evaluate the safety and efficacy of K9-ACV, an autologous killed tumor cell vaccine combined with a novel checkpoint inhibitor (CD200AR-L), compared to standard-of-care chemotherapy for the treatment of canine appendicular osteosarcoma (OSA). K9-ACV has safely been used in over 1,000 dogs, and the vaccine has been shown to display safety in a previous study (without the addition of the checkpoint inhibitor). By evaluating K9-ACV, this trial aims to advance safer, immune-based treatment options for canine cancer that may offer comparable or superior outcomes to chemotherapy.Find more information about this study:https://studypages.com/s/autologous-cancer-vaccine-with-checkpoint-inhibitor-for-treatment-of-canine-osteosarcoma-565406/Adrienne Wright, adrienne@ardentanimalhealth.com, +1 (859) 619-5893
The Real Truth About Health Free 17 Day Live Online Conference Podcast
Discover the neurobiological secrets of revitalizing your mental battery with Michael Nehls, Ph.D. Learn how to harness the fountain of our mental energy, creativity, individuality, and motivation for better performance and well-being. Optimize your brain's potential today! #MentalEnergy #Neurobiology #Motivation
The Elective Rotation: A Critical Care Hospital Pharmacy Podcast
Show notes at pharmacyjoe.com/episode1018. In this episode, I'll discuss andexanet vs. prothrombin complex concentrate for reversal of factor Xa inhibitor-related intracranial hemorrhage. The post 1018: Balancing Risk vs Benefit – Andexanet vs. Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitor-Related Intracranial Hemorrhage appeared first on Pharmacy Joe.
Commentary by Dr. Katie Ruddy.
Commentary by Dr. Jafar Al-Mondhiry.
JACC Associate Editor Khurram Nasir, MBBS, FACC, speaks with author Michael J. Koren, MD, FACC, on his Featured Clinical Research study published in JACC and presented at ACC.25. This randomized, multicenter, double-blind, placebo-controlled, dose-ranging phase 2 study assessed efficacy, safety, and tolerability of AZD0780, a small molecule PCSK9 inhibitor. The study randomized 428 patients (426 started treatment) with hypercholesterolemia on standard-of-care statin therapy to daily oral administrations of AZD0780 1, 3, 10 or 30 mg, or matching placebo for 12 weeks. AZD0780 significantly reduced LDL-C levels versus placebo at all doses (from 35.3% to 50.7%) and demonstrated a safety and tolerability profile similar to placebo. These findings support further development of AZD0780 as part of a simple, oral regimen for lowering LDL-C beyond that achieved with statin therapy.
Appendiceal neoplasms present with peritoneal carcinomatosis and despite aggressive CRS/HIPEC, often recur and are chemotherapy resistant. In this Colorectal DSWG SSO sponsored podcast episode, we discuss an overview of the recent publication of "Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis with GNAS Mutations" by Dr. Lowy's research lab at UCSD. The authors treated 16 patients in this Phase 2 study of oral Palbociclib in recurrent appendiceal adenocarcinoma patients and identified excellent treatment and long-term response with 13/16 of patients treated having reduction in CEA and excellent survival (median FU of 17.6 months, OS not reached). Dr Lowy provides informative background, study details and discusses next steps for this novel treatment approach. A link to the paper in question is https://pubmed.ncbi.nlm.nih.gov/39413348/
Prothrombin complex concentrates (PCCs) are frequently used off label for the management of factor Xa inhibitor-associated major bleeding. In 2018, accelerated approval was granted for andexanet alfa, a specific factor Xa inhibitor reversal agent, for reversal of apixaban and rivaroxaban in the setting of life-threatening or uncontrolled bleeding. Following accelerated approval, some clinical practice guidelines were updated to include recommendations for andexanet alfa preferentially over PCCs for reversal of life-threatening or uncontrolled bleeding due to rivaroxaban or apixaban. Other guidelines stated no preference of andexanet alfa over PCC. In 2020, Vizient convened an expert panel to critically appraise the literature and provide consensus-based, expert opinions on the utilization of pharmacological reversal agents for factor Xa-related major bleeding. Since then, the body of literature evaluating these agents has expanded to include a randomized controlled trial, ANNEXa-I, the results of which were submitted to the US Food and Drug Administration to convert the approval of andexanet alfa from accelerated to full approval. Dr. Lisa Baumann-Kreuziger, Associate Professor of Hematology and Oncology, Medical College of Wisconsin and medical director of the Antithrombotic Therapy Management Program at Froedtert Health discusses the current status of management of factor Xa inhibitor-associated major bleeding with Dr. Kerry Schwarz, Senior Clinical Manager of Evidence-Based Medicine and Outcomes with the Vizient Center for Pharmacy Practice Excellence, and your program host. Guest speakers: Liza Baumann-Kreuziger, MD, MS Investigator, Blood Research Institute, Versiti Associate Professor of Hematology and Oncology, Medical College of Wisconsin Medical Director, Antithrombotic Therapy Management Program at Froedtert Health Host: Kerry Schwarz, Pharm.D, MPH Senior Clinical Manager of Evidence-Based Medicine and Outcomes Vizient Center for Pharmacy Practice Excellence Show Notes: [02:25-04:26] The current state of hemostatic management in the setting of factor Xa inhibitor-related major bleeding [04:27- 05:35] Limitations of available evidence making clinical practice and formulary decision making so challenging [05:35 – 10:52] Publication of the first randomized controlled trial, ANNEXa-I, comparing andexanet alfa to usual care [10:52-14:49] Meeting of the FDA advisory committee and subsequent complete response letter [14:50-16:45] How we can approach clinical management of patients and formulary decision-making in the current state Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed
This activity was supported by an educational grant from Merck & Co., Inc.. Please go to https://academiccme.com/front-matter/epcpah/ and complete the evaluation to receive your CE/CME Credit. Credit is available through September 19, 2025.
Susan Svoboda was accustomed to going in for her mammogram every November. She enjoyed a healthy lifestyle, which included running 65 half marathons. But in late 2021, after her mammogram, she was called to return to the doctor's office. After scans and a biopsy, she was diagnosed with Stage 1-2 invasive ductal carcinoma. Given her healthy routine, Susan was shocked, but she quickly had to turn her attention to her treatment. In 2022, she underwent a successful lumpectomy. Because of the location of the lump, and her low Oncotype DX score, the oncologist told Susan she would not have to undergo chemotherapy. Instead, she would need to get radiation treatment, 15 rounds over three weeks; but her oncologist also suggested her regimen include estrogen inhibitor pills for the next five years. Susan consulted reading materials and talked to numerous women who had tried the pills. All of them had something to say that helped her to make the difficult decision to refuse the estrogen inhibitors. Susan Svoboda found her way to survivorship. She says that while she doesn't do half marathons, she still some light running and goes walking every day. Her journey inspired her to spend 2022 writing a book, “I Hate The Color Pink.” She says the satisfaction that comes from writing the book is its spreading a message of information and hope. By way of advise, Susan advises women to get their mammograms and when dealing with doctors to ask questions, lots of questions. Addition Resources: Susan Book, available on Amazon: “I Hate The Color Pink”
On this episode of the Astonishing Healthcare podcast, Justin Venneri chats with Angela Kalantarova, PharmD, a senior clinical programs manager at Capital Rx, about recent updates to Medicare's star ratings. Angela shares her path to Capital Rx and experience working in managed care and on clinical programs, and she explains what's new for 2025: star measures for polypharmacy and concurrent use of opioids and benzodiazepines.The conversation highlights the positive impact early interventions can have and how innovative enterprise health technology like Judi® allows for real-time insights. As CMS proposes changes, such as possibly removing the MTM - medication therapy management - measure or others like limiting initial opioid supply, having the flexibility to react quickly helps immensely. Angela also provides some strategic insights into how to navigate the evolving landscape and achieve superior ratings.Related ContentAH035 - Pharmacy Benefits 101: Clinical Programs, with Bonnie Hui-Callahan, PharmDPoster: Impact of Point-of-Sale Duplicate Therapy Safety Alert on Concomitant DPP-4 Inhibitor and GLP-1 Agonist UseAH005 - Star Ratings, MTM, & CMS Translation Requirements with Jay Tran, PharmDAH006 - Pharmacy Benefits 101: Clinical Care Teams, with Amy Stockton, PharmDFor more information about Capital Rx and this episode, please visit Capital Rx Insights.
This episode of JACC-Baran features a brief discussion on Kendrick Lamar and the history of racial discrimination in the United States. Then Hiroki Ueyama, MD, from Emory University discusses his study on P2Y12 inhibitor pre-treatment in NST-ACS using data from the Chest Pain-MI Registry. The study examines how guideline changes have influenced clinical practice, revealing a decline in pre-treatment rates, significant practice variations, and no major differences in outcomes except for longer hospital stays in CABG patients. Watch the video or listen as a podcast here, then check out the JACC article: https://www.jacc.org/doi/10.1016/j.jacc.2024.09.1227
CME credits: 1.00 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/nipocalimab-an-fcrn-inhibitor-and-its-role-in-treating-hdfn/32282/ Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother's risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.
Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net. Today on the emDOCs cast with Brit Long (@long_brit), we cover immune checkpoint inhibitors and adverse events. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play
In this podcast, Dr. Valentin Fuster discusses a study on the use of P2Y12 inhibitor pretreatment in patients with non-ST elevation acute coronary syndrome, revealing significant variability in its application across institutions and operators. Despite initial hypotheses of benefit, the findings indicate no significant difference in patient outcomes, suggesting that routine pretreatment may not be necessary, especially when treatment is initiated within 24 hours of symptom onset.
CME credits: 0.50 Valid until: 23-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-treatment-options-for-patients-with-cllsll-and-mcl-that-have-progressed-following-a-covalent-btk-inhibitor/32284/ This enduring activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating CLL/SLL and MCL. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans for patients that have progressed following a covalent BTK inhibitor. The program highlights the importance of evidence-based approaches and the use of noncovalent BTK inhibitors for relapsed/refractory CLL/SLL and MCL. Attendees will also explore emerging data that could influence future treatment guidelines, and a case example of a patient with CLL/SLL relapsing after 2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Although one in five colorectal cancers having microsatellite instability and expressing the Werner Helicase (WRN) gene could be treated with drugs that inhibit WRN, the effectiveness of such an approach has been limited by resistance. However, researchers identified the Cys727 mutation as being solely responsible for WRN inhibitor resistance. This potentially opens the door to using WRN inhibitors in the cancer clinic by inactivating this resistance gene. At the EORTC-NCI-AACR 2024 Molecular Targets and Cancer Therapeutics Symposium Gabriele Picco, PhD, Senior Staff Scientist in the Translational Cancer Genomics Team at the Wellcome Sanger Institute’s Genome Campus, reported findings about WRN resistance mechanisms that may clear the path to introducing WRN inhibitors to the cancer clinic to fight microsatellite unstable cancers.
The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEYNOTE-006 study comparing the anti-PD-L1 antibody pembrolizumab immunotherapy with the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) drug ipilimumab for treating patients with unresectable advanced or metastatic melanoma. Results from the study were reported at the European Society for Medical Oncology (ESMO) 2024 Annual Congress, held in Barcelona, Spain.
VetFolio - Veterinary Practice Management and Continuing Education Podcasts
Sodium–glucose cotransporter (SGLT) 2 inhibitors are an exciting new class of drugs approved for the treatment of newly diagnosed diabetic cats. These drugs work by blocking the kidneys from reabsorbing glucose, which causes more glucose to be lost in urine and lowers blood glucose levels. Tune in to this episode of the VetFolio Voice podcast as host Dr. Cassi and her guest, Dr. Audrey Cook, explore when to consider an SGLT-2 inhibitor instead of insulin and how to successfully manage and monitor a cat receiving this treatment.
The prospect of a minimally toxic, chemotherapy-free cure for hepatoblastoma is held out by findings from a mouse model using the small-molecule drug WNTinib that inhibits the Wnt signaling pathway involved with cancer growth. Lead author Ugnė Balaševičiūtė, a pre-doctoral researcher in Translational Research of the Hepatic Oncology Group led by Josep M. Llovet, Professor at the Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) in Barcelona, Spain, reported that the CTNNB1 (catenin beta-1 protein) gene targeted by WNTinib was expressed in 90 percent of all hepatoblastomas. Hopes were high that a safer alternative to chemotherapy in humans was on the way.
Clone Wars Conversations continues with a vital arc to understanding what actually happened in Order 66; the first four episodes of Season 6! Dave, Maff & Mike talk in-depth about the clone inhibitor chips, Fives and more! In this episode, the trio discuss the premiere of the “final” season (before Season 7 was announced/released) and how this series has brought such life to the many clones, including Fives. They talk about the depth of the conspiracy, Palpatine, the droid AZ, Kamino and what these episodes mean for Revenge Of The Sith & beyond (without detailing Bad Batch, as Dave & Maff have yet to see it). Episodes featured; The Unknown, Conspiracy, Fugitive & Orders. The weekly Skeleton Crew discussion shows continue, with Maff on the episode 4 talk and Dave to appear in 2025! Listen on any podcast app: https://pod.fo/e/29345d or watch on YouTube: https://youtu.be/Q7yoQ0NnjgI Clone Wars Conversations has been releasing monthly since January 21st 2024 on the usual podcast feeds & YouTube (eps 221, 225, 229, 233, 236, 238, 241, 244, 245, 249, 251 & 252 of GCC): https://www.youtube.com/playlist?list=PLcO1Ib_BGD8Y79aRWUxSWwdy3eyNrbXBl The trio are all featuring in various episodes of JAC's Back to The Filmography, each of their first season 2 appearances are out now, for the season of Matthew McConaughey! Dave talks about Dazed & Confused, Maff does Angels In The Outfield and Mike does Glory Daze! Listen to BttF anywhere you find podcasts: https://podfollow.com/1686261095 Mike appeared on Spider-Dan & The Secret Bores for their top 5 small cast movies, listen here: https://pod.fo/e/289237 Mike also appeared on Spider-Dan's pod with Megan, talking Princess Diana in Spencer: https://pod.fo/e/2916c6 Maff is @MaffUK78 on Twitter and recently spoke about Conan comics on 20th Century Geek here: https://pod.fo/e/277fbc - spoke about the TMNT story The Last Ronin on Indie Comics Spotlight here: https://pod.fo/e/24c64a - and did a spider-related podcast with Spider-Dan here: https://pod.fo/e/22733f You can find Dave on Threads @davehorrocks, or the podcasts Comics In Motion, the VHS Strikes Back: https://linktr.ee/vhsstrikesback and Chris & Dave's Reality TV Cast: https://anchor.fm/cdrealitycast Last week on Genuine Chit-Chat & Comics In Motion, Mike interviewed Charles Soule & Ryan Browne about their upcoming Lucky Devils comic! Listen here: https://pod.fo/e/291d48 or watch the video version here: https://youtu.be/K4sUI_zU9L4 Mike has been involved with many other Star Wars podcasts, including interviewing Mike Chen on episode 234 of GCC about his novel Star Wars: Brotherhood and he returns on episode 246 to talk about his latest novel with Marvel; What If Marc Spector Was Host To Venom? Ep 234 found here: https://pod.fo/e/23d985 & https://youtu.be/pQA0QvC5qa0 and ep 246 found here: https://pod.fo/e/279547 & https://youtu.be/PAEmwuhG2gw Find all of Mike's social media & other links at https://linktr.ee/GenuineChitChat Timestamps: 00:00 Intro, Guest Spots & What's To Come 03:02 Season 6 P1 Discussion 01:34:00 Outro
Clone Wars Conversations continues with a vital arc to understanding what actually happened in Order 66; the first four episodes of Season 6! Dave, Maff & Mike talk in-depth about the clone inhibitor chips, Fives and more! In this episode, the trio discuss the premiere of the “final” season (before Season 7 was announced/released) and how this series has brought such life to the many clones, including Fives. They talk about the depth of the conspiracy, Palpatine, the droid AZ, Kamino and what these episodes mean for Revenge Of The Sith & beyond (without detailing Bad Batch, as Dave & Maff have yet to see it). Episodes featured; The Unknown, Conspiracy, Fugitive & Orders. The weekly Skeleton Crew discussion shows continue, with Maff on the episode 4 talk and Dave to appear in 2025! Listen on any podcast app: https://pod.fo/e/29345d or watch on YouTube: https://youtu.be/Q7yoQ0NnjgI Clone Wars Conversations has been releasing monthly since January 21st 2024 on the usual podcast feeds & YouTube (eps 221, 225, 229, 233, 236, 238, 241, 244, 245, 249, 251 & 252 of GCC): https://www.youtube.com/playlist?list=PLcO1Ib_BGD8Y79aRWUxSWwdy3eyNrbXBl The trio are all featuring in various episodes of JAC's Back to The Filmography, each of their first season 2 appearances are out now, for the season of Matthew McConaughey! Dave talks about Dazed & Confused, Maff does Angels In The Outfield and Mike does Glory Daze! Listen to BttF anywhere you find podcasts: https://podfollow.com/1686261095 Mike appeared on Spider-Dan & The Secret Bores for their top 5 small cast movies, listen here: https://pod.fo/e/289237 Mike also appeared on Spider-Dan's pod with Megan, talking Princess Diana in Spencer: https://pod.fo/e/2916c6 Maff is @MaffUK78 on Twitter and recently spoke about Conan comics on 20th Century Geek here: https://pod.fo/e/277fbc - spoke about the TMNT story The Last Ronin on Indie Comics Spotlight here: https://pod.fo/e/24c64a - and did a spider-related podcast with Spider-Dan here: https://pod.fo/e/22733f You can find Dave on Threads @davehorrocks, or the podcasts Comics In Motion, the VHS Strikes Back: https://linktr.ee/vhsstrikesback and Chris & Dave's Reality TV Cast: https://anchor.fm/cdrealitycast Last week on Genuine Chit-Chat & Comics In Motion, Mike interviewed Charles Soule & Ryan Browne about their upcoming Lucky Devils comic! Listen here: https://pod.fo/e/291d48 or watch the video version here: https://youtu.be/K4sUI_zU9L4 Mike has been involved with many other Star Wars podcasts, including interviewing Mike Chen on episode 234 of GCC about his novel Star Wars: Brotherhood and he returns on episode 246 to talk about his latest novel with Marvel; What If Marc Spector Was Host To Venom? Ep 234found here: https://pod.fo/e/23d985 & https://youtu.be/pQA0QvC5qa0 and ep 246 found here: https://pod.fo/e/279547 & https://youtu.be/PAEmwuhG2gw Find all of Mike's social media & other links at https://linktr.ee/GenuineChitChat Timestamps: 00:00 Intro, Guest Spots & What's To Come 03:02 Season 6 P1 Discussion 01:34:00 Outro
CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommendations-for-first-line-treatment-intensification-with-parp-inhibitor-combinations-in-patients-with-metastatic-castration-resistant-prostate-cancer/29196/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-second-line-treatment-following-an-immune-checkpoint-inhibitor-in-renal-cell-carcinoma/29199/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE information, and to apply for credit, please visit us at PeerView.com/VPZ865. CME/CPE credit will be available until December 10, 2025.Optimizing PARP Inhibitor Therapy in Veterans With Prostate Cancer: A Practical Guide for VA Pharmacists In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE information, and to apply for credit, please visit us at PeerView.com/VPZ865. CME/CPE credit will be available until December 10, 2025.Optimizing PARP Inhibitor Therapy in Veterans With Prostate Cancer: A Practical Guide for VA Pharmacists In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE information, and to apply for credit, please visit us at PeerView.com/VPZ865. CME/CPE credit will be available until December 10, 2025.Optimizing PARP Inhibitor Therapy in Veterans With Prostate Cancer: A Practical Guide for VA Pharmacists In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE information, and to apply for credit, please visit us at PeerView.com/VPZ865. CME/CPE credit will be available until December 10, 2025.Optimizing PARP Inhibitor Therapy in Veterans With Prostate Cancer: A Practical Guide for VA Pharmacists In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
When a new drug class enters the veterinary world, first comes the excitement…then comes the learning. In this episode of Clinician's Brief Partner Podcast, Jocelyn Mott, DVM, DACVIM, answers your most frequently asked questions when it comes to using a novel drug class in the treatment of feline diabetes mellitus: the sodium-glucose cotransporter-2 inhibitor. Tune in as she explains when, how, and why to consider this option in newly diagnosed feline diabetics.Sponsored by ElancoResource:https://my.elanco.com/us/bexacatContact us:Podcast@briefmedia.comWhere to find us:Cliniciansbrief.com/podcastsFacebook.com/clinciansbriefTwitter: @cliniciansbriefInstagram: @clinicians.briefThe Team:Beth Molleson, DVM - HostTaylor Argo - Producer & Project Manager, Brief StudioRandall Stupka - Podcast Production & Sound Editing
JACC Associate Editor Seng Chan You, MD, and author Hiroki Ueyama, MD discuss this study presented at AHA and published in JACC. NCDR study finds a steady decline in P2Y12 inhibitor pretreatment for NSTE-ACS in the US, but significant variability persists among operators, institutions, and regions. This practice was not associated with any benefits but was linked to a longer length of stay among those undergoing CABG, underscoring the importance of maintaining efforts to integrate evidence into clinical practice.
Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/
Deborah Siegal, MD, MSc, FRCPC / Richard Body, MBChB, FRCEM, PhD - Turn the Bleed Around: Expert Perspectives on the Evolving Evidence for Management of Factor Xa Inhibitor-Associated Life-Threatening Bleeding
In this episode, Dr. Valentin Foster highlights a groundbreaking study published in the October 2024 issue of JACC, which explores how patiromer facilitates the effective use of angiotensin inhibitors and mineralocorticoid antagonists in heart failure patients at risk of hyperkalemia. Authored by Dr. Bertram Pete and colleagues, the research demonstrates that patiromer not only helps achieve optimal medication doses but also improves potassium management, ultimately enhancing patient outcomes in this high-risk population.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AGR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until September 16, 2025.Making Precision Decisions in High-Risk HR+, HER2- Metastatic Breast Cancer: Practical Training on Individualizing CDK4/6 Inhibitor Treatment to Enhance Adherence, Quality of Life, and Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC
In this episode of the Astonishing Healthcare podcast, Justin Venneri speaks with Bonnie Hui-Callahan, PharmD, CDCES, Senior Director of Clinical Programs at Capital Rx, about the significance of clinical programs within the pharmacy benefit management (PBM) space. Bonnie explains how clinical programs serve as an "added layer of service" similar to after-school programs. They enhance the core functions of PBMs (claim administration) and help plan sponsors reduce costs, improve quality of care, enhance patient safety, and address prevalent health conditions within their populations.The conversation delves into the different types of clinical programs offered by Capital Rx, categorized into five key areas: utilization management, cost containment, patient safety, population health, and personalized care. Bonnie emphasizes that while many programs, such as opioid safety and medication therapy management, are standard across PBMs, there are also unique, in-house, and vendor-partnered solutions tailored to specific health conditions. She also highlights the potential benefits and importance of integrating pharmacy and medical claims, offers some key questions plan fiduciaries can ask, and reviews the results of a recent poster presentation by her team at the 2024 Pharmacy Quality Alliance meeting!Related ContentPoster: Impact of Point-of-Sale Duplicate Therapy Safety Alert on Concomitant DPP-4 Inhibitor and GLP-1 Agonist UseAH005 - Star Ratings, MTM, & CMS Translation Requirements with Jay Tran, PharmDAH006 - Pharmacy Benefits 101: Clinical Care Teams, with Amy Stockton, PharmDPharmacy Benefits 101: Prior AuthorizationsFor more information about Capital Rx and this episode, please visit Capital Rx Insights.
In this week's episode we'll discuss how CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia; learn more about the effect of ATM germline pathogenic variants on the outcomes in children with ataxia-telangiectasia and hematological malignancies; and discuss the preclinical efficacy of a potent, selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias.Featured Articles:CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemiaATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematologicalmalignanciesPreclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) inKMT2A- and NPM1-altered leukemias
Subscribe to our channel: https://www.youtube.com/@optispan Check out the paper: https://www.nature.com/articles/s41586-024-07701-9.pdf Related episodes: The Benefits of Protein Restriction, How Protein Affects Hormones & FGF21: https://youtu.be/Nf1GhkAFiWY A recent paper demonstrating that injecting older mice with an anti-IL-11 drug extended their median lifespan made a splash in the geroscience community this summer. IL-11 is a proinflammatory cytokine that plays a role in regulating various biological processes, including hematopoiesis (the production of blood cells), bone health and remodeling, and tissue repair. Meanwhile, cytokines act as messengers between cells, helping to regulate immune responses, inflammation, and the production of blood cells. In excess or when dysregulated, cytokines can contribute to chronic inflammation and autoimmune diseases. In this episode, Matt discusses the role IL-11 plays in the body, the ERK, AMPK, and mTOR pathways, genetic and pharmacological models of IL-11 reduction, and more. He goes over the paper's claims and provides his take on whether this finding is a game-changer in the longevity field as well as on what further questions he'd like to see answered in follow-up studies. Producers: Tara Mei, Nicholas Arapis Video Editor: Jacob Keliikoa DISCLAIMER: The information provided on the Optispan podcast is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices. More places to find us: Twitter: https://twitter.com/optispanpodcast Twitter: https://twitter.com/optispan Twitter: https://twitter.com/mkaeberlein Linkedin: https://www.linkedin.com/company/optispan https://www.optispan.life/ Hi, I'm Matt Kaeberlein. I spent the first few decades of my career doing scientific research into the biology of aging, trying to understand the finer details of how humans age in order to facilitate translational interventions that promote healthspan and improve quality of life. Now I want to take some of that knowledge out of the lab and into the hands of people who can really use it. On this podcast I talk about all things aging and healthspan, from supplements and nutrition to the latest discoveries in longevity research. My goal is to lift the veil on the geroscience and longevity world and help you apply what we know to your own personal health trajectory. I care about quality science and will always be honest about what I don't know. I hope you'll find these episodes helpful!
Interview with Michelle Rengarajan, MD, PhD, author of Identification of Immune Checkpoint Inhibitor–Induced Diabetes. Hosted by Vivek Subbiah, MD. Related Content: Identification of Immune Checkpoint Inhibitor–Induced Diabetes
Living with pustular psoriasis is tough. Hear the latest updates about heritable aspects of GPP, diagnosis, management tips, and treatment options such as the IL-36 inhibitor spesolimab, how it works and how effective it is from dermatologist Dr. Laura Ferris, Professor of Dermatology at the University of Pittsburgh and moderator Alan Simmons. This episode is provided with support from our Psoriasis Action Month sponsors.
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
On this episode of the Real Life Pharmacology podcast, I cover medications 51-55. They are eszopiclone, celecoxib, estrogen, moxifloxacin, and donepezil. Eszopiclone is a "Z" drug used for insomnia. Its adverse effect profile is very similar to benzodiazepines. Celecoxib is a COX-2 Inhibitor used for pain and inflammation. I discuss how this medication differs from traditional NSAIDs. Estrogen therapy is used for menopausal symptoms but carries a risk of cancer and blood clots. Moxifloxacin is a quinolone antibiotic. Binding drug interactions, boxed warnings, and QTc prolongation are potential concerns. Donepezil is a medication used for dementia. I discuss its mechanism of action and common adverse effects.
Date: July 29, 2024 Reference: Connolly SJ et al (ANNEXA-I investigators) Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage. NEJM May 2024 Guest Skeptic: Dr. Vasisht Srinivasan is an Emergency Medicine physician and neurointensivist at the University of Washington and Harborview Medical Center in Seattle, WA. He is an assistant professor in Emergency Medicine, Neurology, […] The post SGEM#450: Try Again – Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage first appeared on The Skeptics Guide to Emergency Medicine.